Buy Laurus Labs; target of Rs 610: Motilal Oswal
Motilal Oswal is bullish on Laurus Labs recommended buy rating on the stock with a target price of Rs 610 in its research report dated October 22, 2022.24-10-2022
24-10-2022
Laurus Labs: Anti-retroviral business disappoints but synthesis-led growth intact
Capex execution will be key to the company's growth prospects; diversification initiatives should be supportive22-10-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Audio recording of the Q2 FY 23 earnings call hosted on October 21, 202221-10-2022
Laurus Labs Q2 profit up 14% at Rs 233 crore
The company had reported a net profit of Rs 204 crore in July-September period a year ago.21-10-2022
Q2FY23 Quarterly Result Announced for Laurus Labs Ltd.
Pharmaceuticals company Laurus Labs announced Q2FY23 results: H1FY23: Revenue at Rs 3,115 crore, increased 26% (YoY) EBITDA at Rs 903 crore, increased by 21% (YoY) EBITDA margins at 29% PAT at Rs 484 crore, increased by 9% (YoY) PAT margins at 16% EPS (Diluted) (face value of Rs 2/-) for the period at Rs 9.0 per share (not annualised) Interim Dividend of Rs 0.80/- per share. Q2FY23: Revenue at Rs 1,576 crore, increased 31 % (YoY) EBITDA at Rs 449 crore, increased by 29 % (YoY) EBITDA margins at 28.5 % PAT at Rs 233 crore, increased by 15 % (YoY) PAT margins at 15 % EPS (Diluted) for the period at Rs 4.3 per share (not annualised) Commenting on the highlights, Founder and Chief Executive Officer Dr. Satyanarayana Chava stated “In the First Half of 2023 Laurus Lab's delivered healthy results. It reflect our efforts towards strengthening and diversifying our business by increasing revenues from CDMO and Non ARV API and Formulations. ARV FDF performance was very weak, impacted by lower volumes and adverse pricing but we expect good reversal in H2. We are also pleased to update on R&D; progress where we have developed a Novel Delivery for Pediatric HIV treatment and expect to file NDA shortly. This should significantly enhance our market position. Our capital allocation priorities remain unchanged. We will continue to prioritize investments in our pipeline and business within Non-ARVs to realize the value of the several mid and long-term opportunities in front of us. Looking forward to Second Half 2023, we expect to deliver a strong underlying Revenue growth and stable EBITDA margins of ~30% in FY2023." Result PDF21-10-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release21-10-2022
Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Investor Presentation
investor presentation21-10-2022
Laurus Labs Ltd - 540222 - Corporate Action-Board approves Dividend
The Board approved the dividend at the meeting held on October 21, 202221-10-2022
Laurus Labs Ltd - 540222 - Financial Results For Q2 FY 2022-23
Financial Results for Q2 FY 2022-2321-10-2022
Laurus Labs Ltd - 540222 - Board Meeting Outcome for Outcome Of The Board Meeting Held On October 21, 2022
Outcome of the Board Meeting held on October 21, 202221-10-2022